[{"id":"bcad0e5d-8e9a-4e78-8773-942d97532535","acronym":"FUCHSia","url":"https://clinicaltrials.gov/study/NCT03926936","created_at":"2021-01-18T19:20:57.374Z","updated_at":"2024-07-02T16:35:00.857Z","phase":"Phase 2","brief_title":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","source_id_and_acronym":"NCT03926936 - FUCHSia","lead_sponsor":"Frederic Amant","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/27/2022","study_completion_date":" 12/27/2022","last_update_posted":"2024-05-27"},{"id":"ceb4a15f-4948-45ce-a9b8-6d200e3c444c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428192","created_at":"2021-01-18T11:37:00.299Z","updated_at":"2024-07-02T16:35:12.021Z","phase":"Phase 2","brief_title":"Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma","source_id_and_acronym":"NCT02428192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/22/2015","start_date":" 04/22/2015","primary_txt":" Primary completion: 09/20/2018","primary_completion_date":" 09/20/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-04-02"},{"id":"d24439cc-d62c-48da-9580-3c9daa1b29b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05649956","created_at":"2022-12-14T14:58:11.091Z","updated_at":"2024-07-02T16:35:18.156Z","phase":"Phase 2","brief_title":"Letrozole in Uterine Leiomyosarcoma","source_id_and_acronym":"NCT05649956","lead_sponsor":"GOG Foundation","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-02-22"},{"id":"9e07322c-b2f5-4d6e-a442-18155df7e8cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00856050","created_at":"2021-01-18T03:15:42.485Z","updated_at":"2025-02-25T15:49:57.095Z","phase":"Phase 2","brief_title":"Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma","source_id_and_acronym":"NCT00856050","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2017-04-18"}]